Photo from academic.microsoft.com
The regulatory approval of Onpattro, a lipid nanoparticle-based short interfering RNA drug for the treatment of polyneuropathies induced by hereditary transthyretin amyloidosis, paves the way for clinical development of many… Click to show full abstract
The regulatory approval of Onpattro, a lipid nanoparticle-based short interfering RNA drug for the treatment of polyneuropathies induced by hereditary transthyretin amyloidosis, paves the way for clinical development of many nucleic acid-based therapies enabled by nanoparticle delivery.
Keywords:
acid based;
onpattro story;
clinical translation;
story clinical;
nucleic acid;
translation nanomedicines
Journal Title: Nature Nanotechnology
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Nature Nanotechnology
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!